The University of Chicago Header Logo

Connection

Mark Kozloff to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Antibodies, Monoclonal, Humanized.
Mark Kozloff
Connection Strength
0.916
Antibodies, Monoclonal, Humanized
  1. Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study. Pharmacoepidemiol Drug Saf. 2014 Jul; 23(7):726-34.
    View in: PubMed
    Score: 0.078
  2. Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study. Clin Oncol (R Coll Radiol). 2014 Jun; 26(6):323-32.
    View in: PubMed
    Score: 0.077
  3. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2013 Dec; 12(4):248-54.
    View in: PubMed
    Score: 0.075
  4. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012; 17(12):1486-95.
    View in: PubMed
    Score: 0.070
  5. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study. Eur J Cancer. 2012 May; 48(8):1126-32.
    View in: PubMed
    Score: 0.067
  6. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
    View in: PubMed
    Score: 0.064
  7. Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'. Oncology. 2011; 80(1-2):135-7; author reply 140-1.
    View in: PubMed
    Score: 0.064
  8. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010; 78(5-6):329-39.
    View in: PubMed
    Score: 0.060
  9. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010 Mar; 5(3):354-60.
    View in: PubMed
    Score: 0.058
  10. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009 Sep; 14(9):862-70.
    View in: PubMed
    Score: 0.056
  11. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008 Nov 20; 26(33):5326-34.
    View in: PubMed
    Score: 0.053
  12. Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440). Haematologica. 2021 11 01; 106(11):2834-2844.
    View in: PubMed
    Score: 0.033
  13. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 06; 20(6):849-861.
    View in: PubMed
    Score: 0.027
  14. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Invest New Drugs. 2014 Aug; 32(4):700-9.
    View in: PubMed
    Score: 0.019
  15. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 2014 Mar 07; 14:166.
    View in: PubMed
    Score: 0.019
  16. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.019
  17. TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial. Cancer. 2013 Dec 15; 119(24):4290-8.
    View in: PubMed
    Score: 0.019
  18. Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial. Clin Lung Cancer. 2012 Mar; 13(2):123-8.
    View in: PubMed
    Score: 0.016
  19. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.
    View in: PubMed
    Score: 0.015
  20. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009 Mar; 10(3):247-57.
    View in: PubMed
    Score: 0.014
  21. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005 Nov 01; 23(31):8033-40.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.